[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354842-105":59,"doc-detail-354842-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrated-in-silico-and-in-vitro-evaluation-of-genistein-and-apigenin-as-dual-inhibitors-of-parp1-and-esr1-in-breast-cancer","Integrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer","","Breast cancer remains a major cause of cancer-related mortality, driving the search for safer multitarget therapies. Genistein and Apigenin, plant-derived flavonoids, are explored for dual mechanisms targeting PARP1 and ESR1. An integrative workflow combines network pharmacology, onco-omics profiling, protein–protein interaction analysis, molecular docking, and 100 ns MD simulations, with ADMET/toxicity prediction. In HCC1937 triple-negative cells, both compounds show dose-dependent cytotoxicity with mid- to low-micromolar IC50 values, supporting low-toxicity adjuvant potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-in-silico-and-in-vitro-evaluation-of-genistein-and-apigenin-as-dual-inhibitors-of-parp1-and-esr1-in-breast-cancer/354842/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-in-silico-and-in-vitro-evaluation-of-genistein-and-apigenin-as-dual-inhibitors-of-parp1-and-esr1-in-breast-cancer/354842.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What dual targets were evaluated for Genistein and Apigenin in breast cancer?","Question",{"text":112,"@type":113},"The study focuses on PARP1 and ESR1 as central breast cancer targets for the dual inhibition by Genistein and Apigenin.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which in silico and in vitro methods were used to assess the compounds?",{"text":117,"@type":113},"It uses network pharmacology, onco-omics profiling, protein–protein interaction analysis, molecular docking, and 100 ns molecular dynamics, plus ADMET and toxicity predictions. Cytotoxicity was tested in HCC1937 cells using the MTT assay.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the in vitro cytotoxicity findings in HCC1937 triple-negative breast cancer cells?",{"text":121,"@type":113},"Both compounds produced dose-dependent cytotoxicity, with reported IC50 values around 67.01 ± 1.67 µM for Genistein and 70.24 ± 1.45 µM for Apigenin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354842,1790167577,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Arora etal. BMC Pharmacology and Toxicology (2026) 27:7  \n[https://doi.org/10.1186/s40360-025-01082-z](https://doi.org/10.1186/s40360-025-01082-z)  \nBMC Pharmacology and Toxicology  \nRESEARCH Open Access  \nIntegrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer  \nMonica Arora1, Yahya S. Yaseen2, Ammar A. Razzak Mahmood3, Sibghatullah Muhammad Ali Sangi4, Sreeharsha Nagaraja5*, Santosh Prasad Chaudhary Kurmi6 and Shankar Thapa6*  \nAbstract  \nBackground Breast cancer remains a leading cause of cancer-related mortality among women worldwide, highlighting the need for safer multitarget therapies. Genistein (GNT) and Apigenin are plant-derived flavonoids with reported anticancer properties, but their dual mechanisms against key breast cancer targets have not been comprehensively explored.  \nMethods An integrative in silico approach was employed, including network pharmacology, onco-omics profiling, protein–protein interaction analysis, molecular docking, and 100 ns molecular dynamics (MD) simulations, to identify and validate key targets of GNT and Apigenin. Gene expression, immune infiltration, and survival analyses were performed using GEPIA2 and TIMER2 .0. ADMET and toxicity predictions assessed drug-likeness and safety. Cytotoxic activity was evaluated in HCC1937 cells, a triple-negative breast cancer cell line selected to assess estrogen receptor– independent anticancer effects, using the MTT assay.  \nResults Network analysis prioritized PARP1 and ESR1 as central targets. Docking showed strong affinities of Apigenin for PARP1 (–9 .6 kcal/mol) and GNT for ESR1 (–8 .3 kcal/mol) . MD simulations and MM-GBSA confirmed stable binding with favorable free energy (ΔG_bind = − 74.9 kcal/mol) . KEGG enrichment highlighted pathways including estrogen signaling, endocrine resistance, and PI3K–Akt signaling. Both compounds exhibited favorable ADMET profiles and low predicted toxicity. In vitro, GNT and Apigenin produced dose-dependent cytotoxicity against HCC1937 cells with IC50 values of 67.01 ± 1.67 µM and 70.24 ± 1.45 µM, respectively.  \nConclusion These findings demonstrate that GNT and Apigenin modulate key oncogenic pathways through PARP1 and ESR1 interaction and exert cytotoxic effects inTNBC cells. This suggests their potential as low-toxicity adjuvant agents in breast cancer therapy, particularly where endocrine resistance or BRCA1-associated tumor progression is involved.  \nKeywords Apigenin, Breast cancer, ESR1, GNT, Network pharmacology  \n*Correspondence: Sreeharsha Nagaraja[sharsha@kfu.edu.sa](sharsha@kfu.edu.sa)[ ](sharsha@kfu.edu.sa)Shankar Thapa[tshankar551@gmail.com](tshankar551@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nArora et al. BMC Pharmacology and Toxicology (2026) 27:7  \nIntroducti","cbCaip77j7CWvYhD","https://ap.wps.com/l/cbCaip77j7CWvYhD","pdf",4630584,25,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Breast cancer burden and treatment challenges\n## Molecular subtypes and TNBC rationale","[{\"question\":\"What dual targets were evaluated for Genistein and Apigenin in breast cancer?\",\"answer\":\"The study focuses on PARP1 and ESR1 as central breast cancer targets for the dual inhibition by Genistein and Apigenin.\"},{\"question\":\"Which in silico and in vitro methods were used to assess the compounds?\",\"answer\":\"It uses network pharmacology, onco-omics profiling, protein–protein interaction analysis, molecular docking, and 100 ns molecular dynamics, plus ADMET and toxicity predictions. Cytotoxicity was tested in HCC1937 cells using the MTT assay.\"},{\"question\":\"What were the in vitro cytotoxicity findings in HCC1937 triple-negative breast cancer cells?\",\"answer\":\"Both compounds produced dose-dependent cytotoxicity, with reported IC50 values around 67.01 ± 1.67 µM for Genistein and 70.24 ± 1.45 µM for Apigenin.\"}]","Integrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer | PDF",1790114372,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/845bbd3eccd2d65bd6724cd05e4487ea.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b52ce80d2107ac86e56389c00fc5072c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86c867ba4c91e89a97bcd469cf688abd.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ece8044e6d867cf4caee6920d1981fe0.webp",980,1306]